Anastasatu C, Albu A, Burnea D, Didilescu C, Gîrlonţa V, Mihălţan P, Popescu N, Savu A, Udrea S, Păunescu E
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol. 1989 Jul-Sep;38(3):259-64.
In sarcoidosis and other granulomatous non-caseous diseases, the election treatment is immunosuppressive, mainly with cortisones that ensure more than 70% lasting remissions. Continuous use of cortisones for a long time (8-30 months) in high doses leads to serious side effects: gastric and intestinal ulcers, obesity, osteoporosis, suprarenal dysfunction, sensitivity to infections. Good results and elimination of the important side effects were obtained by treatment with Reprimum--a semisynthetic antibiotic with a wide spectrum and immunosuppressive properties--administered alone or with prednisone in small doses (15-20 mg once) in 6 weeks' series: 2 weeks--Reprimum 10/mg/kg daily +/- prednisone and for other 4 weeks--Reprimum 15 mg/kg twice a week +/- prednisone followed by two weeks' break. In 75 patients with histopathologically confirmed sarcoidosis (of whom 7-9.3% with outside-the-lung situs, too), the treatment with Reprimum gave: 94.7% lasting remission, only 5.3% failures, reduction of the treatment period to 6-12 months and the absence of any important side reaction. In other 37 sarcoidosis cases, failures of cortisone therapy (of which 11-30% relapses after 2-6 years), the treatment with Reprimum together with prednisone allowed recovery of 29 patients (78.4%). The same treatment with Reprimum, used in 22 patients with immunosuppressive treatment indication (dermatomyositis, Kaposi's syndrome, thrombocytopenias, nodose periarteritis, silicosis), of whom 18 (81.8%) were failures of the cortisone therapy, healed 20 of these cases (90.9%). Reprimum immunosuppressive property acts at the level of T4+ lymphocyte, involved in sarcoidosis pathogenesis. The functional blockage of T4+ lymphocyte can be also achieved by cyclosporine A.(ABSTRACT TRUNCATED AT 250 WORDS)
在结节病和其他肉芽肿性非干酪样疾病中,首选治疗方法是免疫抑制治疗,主要使用皮质激素,可确保超过70%的患者实现持久缓解。长期(8 - 30个月)大剂量持续使用皮质激素会导致严重的副作用:胃肠道溃疡、肥胖、骨质疏松、肾上腺功能障碍、对感染敏感。使用Reprimum治疗取得了良好效果并消除了重要副作用。Reprimum是一种具有广谱和免疫抑制特性的半合成抗生素,单独使用或与小剂量(一次15 - 20毫克)泼尼松联合使用,按6周疗程给药:前2周,每日给予Reprimum 10毫克/千克±泼尼松;接下来4周,每周两次给予Reprimum 15毫克/千克±泼尼松,然后休息2周。在75例经组织病理学确诊的结节病患者中(其中7 - 9.3%为肺外病变),使用Reprimum治疗的结果为:94.7%实现持久缓解,仅5.3%治疗失败,治疗周期缩短至6 - 12个月,且无任何重要副作用。在另外37例结节病病例中,皮质激素治疗失败(其中11 - 30%在2 - 6年后复发),使用Reprimum联合泼尼松治疗使29例患者(78.4%)康复。同样的Reprimum治疗方法用于22例有免疫抑制治疗指征的患者(皮肌炎、卡波西肉瘤、血小板减少症、结节性动脉周围炎、矽肺),其中18例(81.8%)为皮质激素治疗失败,治愈了其中20例(90.9%)。Reprimum的免疫抑制作用在参与结节病发病机制的T4 +淋巴细胞水平发挥作用。环孢素A也可实现T4 +淋巴细胞的功能阻断。(摘要截选至250字)